Lexeo Therapeutics, Inc./$LXEO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Ticker
$LXEO
Sector
Primary listing
Employees
59
Headquarters
Website
LXEO Metrics
BasicAdvanced
$427m
-
-$1.86
2.00
-
Price and volume
Market cap
$427m
Beta
2
52-week high
$10.99
52-week low
$2.43
Average daily volume
970k
Financial strength
Current ratio
11.208
Quick ratio
10.814
Long term debt to equity
2.113
Total debt to equity
3.197
Interest coverage (TTM)
-1,150.07%
Profitability
EBITDA (TTM)
-108.669
Management effectiveness
Return on assets (TTM)
-32.86%
Return on equity (TTM)
-55.00%
Valuation
Price to book
1.71
Price to tangible book (TTM)
1.71
Price to free cash flow (TTM)
-3.128
Free cash flow yield (TTM)
-31.97%
Free cash flow per share (TTM)
-1.845
Growth
Earnings per share change (TTM)
-39.76%
3-year earnings per share growth (CAGR)
-62.86%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lexeo Therapeutics, Inc. stock?
Lexeo Therapeutics, Inc. (LXEO) has a market cap of $427M as of May 05, 2026.
What is the P/E ratio for Lexeo Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Lexeo Therapeutics, Inc. (LXEO) stock is 0 as of May 05, 2026.
Does Lexeo Therapeutics, Inc. stock pay dividends?
No, Lexeo Therapeutics, Inc. (LXEO) stock does not pay dividends to its shareholders as of May 05, 2026.
When is the next Lexeo Therapeutics, Inc. dividend payment date?
Lexeo Therapeutics, Inc. (LXEO) stock does not pay dividends to its shareholders.
What is the beta indicator for Lexeo Therapeutics, Inc.?
Lexeo Therapeutics, Inc. (LXEO) has a beta rating of 2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.